Proceeds will drive ongoing development and acceleration of Immutep’s immuno-oncology
and autoimmune programs
• Recently announced TACTI-002 data supports accelerating the clinical program into larger
settings
• In collaboration with Merck & Co (“MSD”), Immutep will expand the TACTI-002 trial following
encouraging data from 1st Line non-small cell lung cancer (NSCLC)
• In addition, and following the ongoing strength of the data Immutep will initiate a new phase
2 clinical trial in Head and Neck Squamous Cell Carcinoma (HNSCC)
• Immutep’s product candidates (including partnered products) are currently in 10 active clinical
trials with further significant data read outs in 2020 and 2021
Underline and bold words seem to sound pretty good serious statements no to ignore...
Proceeds will drive ongoing development and acceleration of...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 33.5¢ | $1.174M | 3.359M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 44 | 1273268 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 204887 | 26 |
View Market Depth
| Last trade - 13.26pm 18/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |